HOUSTON — The benefits of SGLT2 inhibitors in slowing kidney disease progression are similar regardless of patients’ type 2 diabetes (T2D) or albuminuria status, the results of a recent meta-analysis ...

HOUSTON -- SGLT2 inhibitors may hold a benefit for a wider pool of patients with chronic kidney disease (CKD) than previously thought, a pair of meta-analyses indicated. SGLT2 inhibitors helped to ...

Treating kidney disease GLP-1s show higher risk than SGLT2 inhibitors in kidney outcomes, but lower albuminuria and mortality rates.

While proven to help, primary care clinicians have been slow to use the drugs once considered only for patients with diabetes.

In a study from Korea, adults with type 2 diabetes had a lower risk for autoimmune rheumatic diseases after starting an SGLT2 inhibitor rather than a sulfonylurea. Over 15,000 adults would need to be ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...